AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $178.94
- 52-wk high
- $191.94
- High
- $178.94
- 52-wk low
- $124.47
- Low
- $175.67
- Prev close
- $179.80
- Mkt cap
- $48.44B
- P/E
- 30.5x
- Volume
- 1.71M
- Fwd P/E
- 13.3x
- Beta
- 0.28
- Div yield
- 2.38%
- P/S
- 2.2x
- P/B
- 2.0x
- Profit margin
- +4.2%
- Op margin
- +15.7%
- ROE
- +6.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 12.9% below what analysts expected.
Earnings per share
$3.33 expected
Revenue
$4.89B expected
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
GAAP EPS was $1.64 and adjusted EPS was $3.23. The adjusted figure is comparable to consensus.
Reports Nov 5, 2026, in 53 days
EPS expected
$4.03 to $4.11
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $5.89B | $5.25B | $4.71B | $4.98B |
| Cost of what it sold | $3.09B | $2.91B | $2.56B | $2.67B |
| Gross profit | $2.80B | $2.34B | $2.15B | $2.31B |
| What it spent | ||||
| Research and development | $322.0M | $318.0M | $249.0M | $258.0M |
| Sales and admin | $1.37B | $1.43B | $1.21B | $1.26B |
| Other operating costs | $414.0M | — | $599.0M | $133.0M |
| Total operating expenses | $2.10B | $1.75B | $2.06B | $1.65B |
| What was left | ||||
| Operating profit | $697.0M | $594.0M | $94.0M | $663.0M |
| Interest on debt | $155.0M | $107.0M | $149.0M | $132.0M |
| Profit before tax | $510.0M | $487.0M | $39.0M | $554.0M |
| Tax | $17.0M | $105.0M | $76.0M | $103.0M |
| Net profit | $493.0M | $382.0M | -$311.0M | $377.0M |
| EBITDA | $1.29B | $1.21B | $709.0M | $686.0M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Omnicell at Wells Fargo healthcare conference: betting on refresh cycle
NeutralSep 9Transcript : Becton, Dickinson and Company Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 09
NeutralSep 9Becton Dickinson & Co's Dividend Analysis
BullishSep 9Becton Dickinson & Co's Dividend Analysis
BullishSep 9Is West Pharmaceutical Services (WST) Stock A Bargain Or Fully Priced?
NeutralSep 8Becton Dickinson (NYSE: BDX) CFO reports 190-share tax withholding
NeutralSep 4USI Named a Top-Rated Provider of the BD® PureWick® Urine Collection System with 99.87% Patient Satisfaction Rate
NeutralSep 1Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
BullishAug 31
Macro
20 macro signals shaping BDX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results